Periprosthetic Joint Infection: Prevention and Management Strategies

Periprosthetic joint infection (PJI) is a severe complication that can occur after joint replacement surgery, leading to significant pain, disability, and even mortality. PJI affects more than 2% of arthroplasty patients 1, and with the growing number of joint replacement surgeries performed worldwide, the incidence of PJI is expected to rise substantially 2. In the United States, the risk of PJI within one year after total hip arthroplasty (THA) is 0.7%, increasing to 1.1% within five years. For total knee arthroplasty (TKA), the corresponding risks are 0.7% within one year and 1.4% within five years 3. The one-year and five-year survival rates after a PJI diagnosis are 88.7% and 67.2% for THA and 91.7% and 71.7% for TKA, respectively 3. Establishing a correct diagnosis of PJI is crucial to ensure appropriate treatment and avoid unnecessary interventions in patients with aseptic failure 4. This article reviews the current best practices for preventing and managing PJI, including antibiotic prophylaxis, surgical techniques, and two-stage revision protocols. It also discusses the role of biofilm and its impact on treatment outcomes.

Antibiotic Prophylaxis

Antibiotic prophylaxis is a cornerstone in preventing PJI. The goal is to reduce the number of bacteria that may contaminate the surgical site during and after surgery. Current recommendations emphasize appropriate patient selection and risk stratification to determine the need for antibiotic prophylaxis 5. The choice of antibiotic, timing of administration, and duration of treatment should be tailored to the individual patient's risk factors and the specific surgical procedure 5.

Best Practices for Antibiotic Prophylaxis

A survey of Canadian surgeons revealed that most prefer a first-generation cephalosporin, such as cefazolin, for antibiotic prophylaxis in total joint replacement surgery 6. However, the most frequently used dose was 1 g, whereas the literature supports a larger dose of 2 g intravenously 6.

The following table summarizes the recommendations for antibiotic prophylaxis in total joint replacement surgery:

Recommendation Details Source
Antibiotic Choice Cefazolin or cefuroxime; Clindamycin or vancomycin if penicillin allergy confirmed 6
Administration Timing IV start within 1 hour of incision (within 2 h for vancomycin); Infuse completely before tourniquet inflation 6
Dosage Adjustment If weight > 80 kg, double dose for cefazolin; Additional dose if operating time exceeds 2–4 hours (6–12 h for vancomycin) or significant blood loss 6
Duration Should not exceed 24 hours postoperative 6
Specific Dosages 2 g cefazolin, 1.5 g cefuroxime, 15 mg/kg vancomycin 6

It is crucial to achieve and sustain the minimum inhibitory concentration (MIC) of antibiotics to maintain antimicrobial susceptibility 7. This is achieved by administering the correct dose at the right time. The initial two hours following an incision are critical for potential pathogen introduction, emphasizing the importance of prompt antibiotic administration, typically within 60 minutes before the surgical incision 7.

Patients with certain conditions, such as a prior history of joint infection, weakened immune system, chronic steroid usage, malnutrition, or inflammatory arthritis, may require antibiotic prophylaxis for an extended period, potentially lifelong 8. These patients may need antibiotic prophylaxis for dental procedures (cleaning, extractions, implants, periodontal work), gastrointestinal procedures (upper endoscopy, colonoscopy), and genitourinary procedures (cystoscopy, TURP) 8.

For patients not allergic to penicillin, 2 g of Amoxicillin is recommended one hour before the procedure. For those allergic to penicillin, 600 mg of Clindamycin is recommended one hour before the procedure 8. Elective dental procedures should be avoided for at least 3 months following joint replacement 8.

Historically, antibiotic prophylaxis was recommended for patients with prosthetic joint implants before dental procedures to prevent infective endocarditis 9. However, a 2015 ADA clinical practice guideline states that "prophylactic antibiotics are not recommended prior to dental procedures to prevent prosthetic joint infection" 9.

The American Heart Association (AHA) no longer recommends clindamycin as an alternative to amoxicillin or ampicillin for individuals with allergies to these drugs due to the potential for more frequent and severe reactions 9. Instead, the AHA recommends cephalexin, azithromycin, clarithromycin, or doxycycline as oral alternatives and cefazolin or ceftriaxone as parenteral alternatives 9. However, cephalosporins should be avoided in individuals with a history of anaphylaxis, angioedema, or urticaria with penicillin or ampicillin 9.

If a patient inadvertently misses premedication before a dental procedure, the antibiotic may be administered up to 2 hours after the procedure 9. If a patient requires antibiotic prophylaxis for multiple dental procedures on consecutive days, the antibiotic prophylaxis regimen should be repeated before each procedure 9.

Close monitoring of patients receiving IV antibiotics outside the hospital setting is essential to ensure treatment effectiveness and safety 10.

Antibiotic-Loaded Cement (ABLC)

The use of antibiotic-loaded cement (ABLC) in primary TJR is another strategy to prevent PJI 6. ABLC is bone cement that contains antibiotics, which are released over time to help prevent infection. However, there is no consensus on the optimal choice of antibiotic for ABLC 6. Some surgeons use ABLC for all primary TJR procedures, while others reserve it for patients at high risk of infection 6.

Surgical Techniques

Surgical techniques are critical in preventing PJI. A meticulous approach to minimize bacterial contamination and optimize tissue handling is essential.

Best Practices for Surgical Techniques

The following list summarizes the key surgical techniques to minimize the risk of PJI:

  1. Preoperative Optimization:

  2. Identify and address modifiable risk factors, such as uncontrolled diabetes, hypertension, malnutrition, high body mass index, corticosteroid use, immunosuppression, chronic liver disease, or chronic kidney disease 11.

    1. Optimize glycemic control using HbA1C and fructosamine as biomarkers 11.
    2. Treat active infections in the body, such as urinary tract infections, oral cavity infections, and nail or skin infections 11.

  3. Reducing Bioburden:

  4. Use preoperative skin cleansing agents and remove hair on the day of surgery 12.

    1. Apply chlorhexidine-impregnated gauze for pre-admission skin preparation 5.

  5. Intraoperative Strategies:

  6. Administer perioperative antimicrobial prophylaxis 12.

    1. Handle tissues gently to avoid damage 12.
    2. Perform surgery expeditiously to minimize operative time 12.
    3. Control blood loss using tranexamic acid and hemostatic agents 13.
    4. Maintain a less crowded operating room environment 13.
    5. Irrigate the wound with an antiseptic solution 13.
    6. Ensure proper cleaning of implants and instruments 13.

  7. Postoperative Care:

  8. Optimize wound care, including keeping the wound clean and dry and using appropriate dressings 13.

In addition to these measures, the following factors can also play a critical role in minimizing the risk of PJI:

  1. Postoperative glycemia control 13
  2. Management of immunosuppression 13
  3. Appropriate management of obesity 13
  4. Management of malnutrition 13
  5. Management of metabolic syndrome 13
  6. Preoperative anemia management 13
  7. Smoking cessation 13

The following table summarizes expert opinions on various measures for PJI prevention:

Statement Score
There should be strict measures to limit the risk of contamination when the patient is transferred from the ward to the operating room 85%
Hair removal should be undertaken (if necessary) immediately prior to entering the operating room 78%
Hair removal is only recommended using clippers, not razors 91%
Surgical hand preparation should be achieved via the use of alcohol-based solutions to improve the prevention of PJI 95%
Antibiotics should always be administered prophylactically to the patient prior to surgery 97%
Incise drapes should not be mandatory in total joint replacement surgery 63%
Disposable drapes should be mandatory in total joint replacement surgery 92%
Devices or surgical drains that interact with the wound site should be avoided 83%
The use of tranexamic acid or hemostatic agents makes the use of surgical drains optional 82%
Decreasing hematoma (using tranexamic acid, hemostatic agents, or other) helps to reduce the risk of infection and avoid wound healing complications 98%
The choice of skin suturing technique strongly impacts the risk of PJI 61%
Shortening the surgical procedure duration reduces the risk of PJI in total joint replacement procedures 98%
Traffic should be kept minimal in the operating room during the time of surgery 99%
Prolonging surgical antibiotic prophylaxis does not reduce the risk of PJI in total joint replacement surgery 91%
Using advanced wound dressings reduces the risk of PJI in total joint replacement surgery 81%
The surgeon should review the patient's operative wound periodically during the first month post-surgery 69%
Knowing and monitoring PJI rates proactively is essential to effective prevention 96%
PJI occurrences should be reported in a structured way in the surgical department 98%
An infection that appears >30 days post-surgery is not considered to be a PJI 15%

Anti-infective Implants

"Anti-infective" implants are an emerging technology that may offer additional protection against PJI 14. These implants are designed to release antimicrobial agents or have surface modifications that inhibit bacterial adhesion and biofilm formation.

Two-Stage Revision Protocols

Two-stage revision is the most common surgical treatment for chronic PJI 15. It involves two separate surgeries:

First Stage: The infected prosthesis is removed, and the joint is thoroughly cleaned. An antibiotic-impregnated spacer is then placed in the joint.

Second Stage: A new prosthesis is implanted after the infection has been eradicated and the soft tissues have healed.

Timing of the Two Stages

The timing of the two stages is crucial. The first stage should be performed as soon as possible after the diagnosis of PJI. The second stage should be performed after the infection is eradicated and the soft tissues have healed, typically taking several weeks to months 16.

Some studies suggest that the optimal timing for the second-stage surgery is between 4 and 11 weeks 17. However, the time to reimplantation (TTR) reported in the literature varies substantially, ranging from a few days to several hundred days 16. Factors such as comorbidities, clinical examination, laboratory results, and organizational factors can influence the TTR 16.

Antibiotic Spacers

Antibiotic spacers are used in two-stage revision to deliver high concentrations of antibiotics to the infected joint. They can be static or dynamic, preformed or handmade, and may replace one or both sides of the joint 15. The choice of spacer depends on factors such as bone loss, ligament laxity, and soft tissue compromise 15.

Criteria for Reimplantation

The decision to proceed with reimplantation in two-stage revision is based on several factors, including:

  1. Resolution of symptoms 18
  2. Normalization of inflammatory markers, such as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) 18
  3. Radiographic findings suggesting no ongoing infection 18
  4. Negative aspiration cultures obtained at least 2 weeks after the planned antibiotic course 19

It is important to obtain a prerevision sedimentation rate and CRP to assess the success of treatment before reimplantation 10. In some cases, more than one two-stage exchange may be necessary to achieve successful eradication of the infection 10.

The interim period between the two stages can significantly impact patient mobility, often leading to temporary dependency 20.

Challenges and Controversies in the Management of PJI

Despite advances in PJI management, several challenges and controversies remain:

Emergence of Antibiotic Resistance

Antibiotic resistance is a growing concern in PJI management 21. Studies have shown that antibiotic resistance is encountered in more than half of PJI cases, affecting all common microorganisms 21. The success of treatment decreases significantly when antibiotic-resistant microorganisms are isolated or when cultures are negative 21.

Role of Biofilm

Biofilm formation by causative pathogens is a major challenge in PJI management 1. Biofilms protect bacteria from antibiotics and the host immune system, making eradication difficult 1.

Optimal Duration of Antibiotic Treatment

The optimal duration of antibiotic treatment for PJI is still debated 22. Some studies suggest that longer courses of antibiotics are more effective, while others support shorter durations 22. Current evidence suggests that antibiotic therapy after debridement and implant retention may need to be lifelong 23. However, there may be a subgroup of patients who can stop antibiotics and remain in remission, but it is currently not possible to accurately identify these patients 23.

Point-of-Care Testing (POCT)

Point-of-care testing (POCT) offers the potential for rapid PJI diagnosis 3. POCT devices can provide quick results, enabling timely management decisions. However, challenges remain regarding the variability in test performance and the need for validation under different clinical scenarios 3.

Hyperbaric Oxygen Therapy

Hyperbaric oxygen therapy (HBOT) is an adjunctive therapy that may improve treatment outcomes in PJI 5. HBOT involves breathing 100% oxygen in a pressurized chamber, which increases the amount of oxygen delivered to tissues. This can promote healing and help fight infection.

Fungal PJIs

Managing fungal PJIs presents unique challenges 4. These infections require prolonged antifungal chemotherapy with antibiotics for bacterial superinfection coverage 4.

Chronic Suppressive Therapy

Decisions about chronic suppressive therapy should consider the patient's ability to use rifampin in the initial phase of treatment, the potential for progressive implant loosening and loss of bone stock, and the hazards of prolonged antibiotic therapy 10. There is no unanimous agreement among experts regarding the use of suppressive therapy after rifampin treatment 10.

Indefinite chronic oral antimicrobial suppression may follow the initial treatment regimen with cephalexin, dicloxacillin, co-trimoxazole, or minocycline, based on in vitro susceptibility, allergies, or intolerances 10. Rifampin alone is not recommended for chronic suppression, and rifampin combination therapy is generally not recommended 10.

Other Challenges

Other challenges in PJI management include:

  1. Medical frailty and advanced age of patients 1
  2. Delays in surgery for acute infection 1
  3. Difficulty in eradicating resistant or difficult-to-treat organisms 1
  4. The increasing medical complexity of patients undergoing arthroplasty 1
  5. The need for a multidisciplinary approach involving orthopedic surgeons, infectious disease specialists, and potentially plastic surgeons 4
  6. The lack of a "gold standard" for diagnosing chronic PJI 24
  7. The need for personalized treatment strategies tailored to individual patient risk factors 25

The Role of Biofilm

Biofilm is a complex matrix of bacteria that can form on the surface of implants. It plays a significant role in PJI pathogenesis by protecting bacteria from antibiotics and the host immune system.

Biofilm Formation

Bacterial biofilms consist of one or more microbial species embedded within a self-produced matrix of extracellular polymeric substances (EPS) 4. This matrix comprises various components, including exopolysaccharides, proteins, teichoic acid, lipids, and extracellular DNA (eDNA) 4. Bacteria adhere to implant surfaces and form biofilms via surface features such as pili, fimbriae, flagella, and glycocalyx 4. These biofilms can grow up to 100 µm thick, and the bacteria within them can be up to 1000 times more resistant to antimicrobial agents than planktonic bacteria 4.

Biofilm's Impact on PJI

Biofilm contributes to PJI formation in several ways:

  1. It shields microorganisms from phagocytosis by the innate immune system 4.
  2. The biofilm matrix acts as an ion-exchange resin, sequestering antibiotics and reducing their effective concentration at the infection site 4.
  3. It can induce the host to produce excessive amounts of inflammatory mediators, contributing to tissue damage and impaired healing 4.

Strategies for Biofilm Eradication

Several strategies are being developed to eradicate biofilm in PJI:

  1. Antibiotics that Penetrate Biofilm: Some antibiotics, such as rifampin, can penetrate biofilm and kill bacteria 10.
  2. Anti-biofilm Agents: These agents can break down the biofilm matrix, making it easier for antibiotics to reach the bacteria 26.
  3. Physical Removal Methods: These include surgical debridement, ultrasound therapy, and laser therapy 27.

One promising approach is the use of a hydrogel with nanoparticles that disrupts the biofilm matrix and enhances antibiotic penetration 27. This hydrogel, combined with laser exposure, has shown significant efficacy in reducing biofilm and infection in a model of knee PJI 27.

Another potential strategy involves combining magnetic hyperthermia and an amino acid gel to disrupt biofilm activity 28. This approach utilizes nanoparticles that generate localized heat upon exposure to a magnetic field, modifying bacterial cell surfaces and biofilm structure 28.

Conclusion

PJI is a serious complication with significant implications for patients and the healthcare system. The increasing number of joint replacement surgeries performed worldwide necessitates a comprehensive approach to PJI prevention and management. Antibiotic prophylaxis, meticulous surgical techniques, and two-stage revision protocols are essential components of PJI management. However, challenges such as antibiotic resistance and biofilm formation require ongoing research and the development of novel strategies.

A multidisciplinary approach involving orthopedic surgeons, infectious disease specialists, and potentially plastic surgeons is crucial for effective PJI management. Early and accurate diagnosis, personalized treatment strategies tailored to individual patient risk factors, and ongoing surveillance and reporting of PJI rates are essential for improving patient outcomes.

Key takeaways for clinicians include:

  1. Adhering to best practices for antibiotic prophylaxis, including appropriate patient selection, antibiotic choice, dosage, and timing of administration.
  2. Implementing meticulous surgical techniques to minimize bioburden and optimize tissue handling.
  3. Carefully considering the timing of the two stages in two-stage revision protocols and selecting appropriate antibiotic spacers.
  4. Recognizing the role of biofilm in PJI pathogenesis and exploring novel strategies for biofilm eradication.
  5. Addressing the challenges of antibiotic resistance and individualizing treatment plans based on patient-specific factors.

By staying informed about the latest research and incorporating best practices into clinical practice, healthcare professionals can contribute to reducing the burden of PJI and improving the lives of patients undergoing joint replacement surgery.

Works cited

1. Periprosthetic Joint Infection: Current Clinical Challenges - PMC, accessed February 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11004930/

2. The Challenge of Periprosthetic Joint Infection Diagnosis: From Current Methods to Emerging Biomarkers - MDPI, accessed February 17, 2025, https://www.mdpi.com/1422-0067/24/5/4320

3. Point of care testing for the diagnosis of periprosthetic joint infections: a review | SICOT-J, accessed February 17, 2025, https://www.sicot-j.org/articles/sicotj/full_html/2024/01/sicotj240041/sicotj240041.html

4. Periprosthetic Joint Infection Diagnosis: A Narrative Review - MDPI, accessed February 17, 2025, https://www.mdpi.com/2079-6382/12/10/1485

5. Preoperative Risk Factors for Periprosthetic Joint Infection: A ... - MDPI, accessed February 17, 2025, https://www.mdpi.com/2227-9032/12/6/666

6. Antibiotic prophylaxis for total joint replacement surgery: results of a survey of Canadian orthopedic surgeons - National Institutes of Health (NIH), accessed February 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2792394/

7. Antibiotics Prophylaxis Practice in Arthroplasty Surgeries - PMC, accessed February 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10936957/

8. Antibiotic Prophylaxis Protocol after Total Joint Replacement - Robert Mayle MD, accessed February 17, 2025, https://www.robertmaylemd.com/antibiotic-prophylaxis-protocol-after-total-joint-replacement.html

9. Antibiotic Prophylaxis Prior to Dental Procedures, accessed February 17, 2025, https://www.ada.org/resources/ada-library/oral-health-topics/antibiotic-prophylaxis

10. Diagnosis and Management of Prosthetic Joint Infection: Clinical Practice Guidelines by the Infectious Diseases Society of Americaa - Oxford Academic, accessed February 17, 2025, https://academic.oup.com/cid/article/56/1/e1/415705

11. "In My Experience...Top Ten Steps for Prevention of Surgical Site Infection after Joint Arthroplasty" | Published in Journal of Orthopaedic Experience & Innovation, accessed February 17, 2025, https://journaloei.scholasticahq.com/article/92106-in-my-experience-top-ten-steps-for-prevention-of-surgical-site-infection-after-joint-arthroplasty

12. Top 10 tips to avoid periprosthetic joint infection - British Orthopaedic Association, accessed February 17, 2025, https://www.boa.ac.uk/static/9d943a8a-2dda-49c1-ad390fb3e0129794/Top-10-tips-to-avoid-periprosthetic-joint-infection.pdf

13. Evidence-based Approach for Prevention of Surgical Site Infection - Hip & Pelvis, accessed February 17, 2025, https://www.hipandpelvis.or.kr/journal/view.html?volume=36&number=3&spage=161

14. Prevention of Prosthetic Joint Infection: From Traditional Approaches towards Quality Improvement and Data Mining - PubMed Central, accessed February 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7408657/

15. Two stage revision: indications, techniques and results - Franceschini - Annals of Joint, accessed February 17, 2025, https://aoj.amegroups.org/article/view/6267/html

16. Is long time to reimplantation a risk factor for reinfection in two-stage revision for periprosthetic infection? A systematic review of the literature - Frontiers, accessed February 17, 2025, https://www.frontiersin.org/journals/surgery/articles/10.3389/fsurg.2023.1113006/full

17. pmc.ncbi.nlm.nih.gov, accessed February 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10763399/#:~:text=Ines%20et%20al.%20reported%20that,78%20months)%20%5B30%5D.

18. Optimal reimplantation timing in two-stage exchange for periprosthetic joint infection: an observative cohort study in Asian population - PMC, accessed February 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10763399/

19. Prosthetic Joint Infection - Recon - Orthobullets, accessed February 17, 2025, https://www.orthobullets.com/recon/5004/prosthetic-joint-infection

20. A Modified Technique for Two-Stage Revision in Knee PJI Treatment - MDPI, accessed February 17, 2025, https://www.mdpi.com/2077-0383/12/23/7323

21. What Is the Rate of Antimicrobial Resistance of a Prosthetic Joint Infection in a Major Orthopaedic Centre? - PubMed, accessed February 17, 2025, https://pubmed.ncbi.nlm.nih.gov/38666982/

22. Truth in DAIR: Duration of Therapy and the Use of Quinolone/Rifampin-Based Regimens After Debridement and Implant Retention for Periprosthetic Joint Infections - Oxford Academic, accessed February 17, 2025, https://academic.oup.com/ofid/article/9/9/ofac363/6649571

23. Prolonged antibiotic suppression therapy for infected hip and knee arthroplasty: is this a viable option? - Annals of Joint, accessed February 17, 2025, https://aoj.amegroups.org/article/view/6227/html

24. Editorial: Management of PJI/SSI After Joint Arthroplasty - Jefferson Digital Commons, accessed February 17, 2025, https://jdc.jefferson.edu/cgi/viewcontent.cgi?article=1259&context=rothman_institute

25. Prevention of Periprosthetic Joint Infection in Total Hip and Knee Replacement: One European Consensus - PMC, accessed February 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8781876/

26. Studying Biofilm and Clinical Issues in Orthopedics - Frontiers, accessed February 17, 2025, https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2019.00359/full

27. Hydrogel With Nanoparticles Reduces Bacterial Biofilm in Model of Periprosthetic Joint Infection - Consult QD, accessed February 17, 2025, https://consultqd.clevelandclinic.org/hydrogel-with-nanoparticles-reduces-bacterial-biofilm-in-model-of-periprosthetic-joint-infection

28. A Potential Treatment for Periprosthetic Joint Infection after Total Joint Arthroplasty, accessed February 17, 2025, https://consultqd.clevelandclinic.org/a-potential-treatment-for-periprosthetic-joint-infection-after-total-joint-arthroplasty